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C-reactive protein (CRP), an acute-phase reactant, has been identiﬁed as a saliva-based biomarker of inﬂammation. The objective
of the study was to estimate and compare salivary CRP levels in Hashimoto’s thyroiditis (HT) and Subacute thyroiditis (SAT). The
studyincluded 30HTpatientswhopresentedwith clinical featuresofhypothyroidism,15SATpatientswho presentedwithclinical
features of hyperthyroidism, and 20 healthy age- and sex-matched euthyroid controls. CRP levels in saliva were estimated using
an Enzyme-Linked Immunosorbent Assay method with enhanced sensitivity. In HT, the mean salivary CRP levels did not diﬀer
signiﬁcantly from controls. SAT patients had signiﬁcantly elevated salivary CRP levels compared to HT patients and controls. The
rise in salivary CRP levels in SAT patients conceivably reﬂects the presence of an inﬂammatory process. Saliva CRP levels appear
to serve as inﬂammatory markers in SAT patients and may aid their clinical evaluation.
1.Introduction
Hashimoto’s thyroiditis (HT) is one of the most com-
mon human autoimmune diseases responsible for con-
siderable morbidity [1, 2]. It is characterized by diﬀuse
lymphocytic inﬁltration of the thyroid gland, elevated
levels of the serum antithyroid antibodies, clinical evi-
dence of goitrous or atrophic gland, and frequent thyroid
dysfunction in varying degrees [2]. Subacute thyroiditis
(SAT) is an acute inﬂammatory disorder of the thyroid
gland most likely due to viral infection [3], character-
ized by painful toxic goiter with systemic inﬂammation
[4].
Acute-phase reactants have been implicated for their
involvement as proinﬂammatory molecules in various
inﬂammatory diseases [5]. Serum C-reactive protein (CRP),
the classical acute-phase protein of hepatic origin, is a
nonspeciﬁc marker of inﬂammation in the body [6, 7].
A sc h a n g e si ns e r u mC R Pl e v e l sr e ﬂ e c tt h ep r e s e n c ea n d
intensity of inﬂammation, CRP has been used as a clinical
marker to assess the inﬂammatory status in many diseases.
CRP estimations have not been routinely used to monitor
thyroid disease, although many thyroid conditions involve
inﬂammation.
Saliva has been shown to contain systemically-derived
biomarkers ofinfectious diseases [8–10].Salivaassaysystems
require necessary sensitivities for the detection of biomark-
ers present at low, but still pathophysiologically relevant,
concentrations in saliva. In the present study, a newly
developed Enzyme-Linked ImmunoSorbent Assay (ELISA)
method with a low limit of detection for CRP was used for
its estimation in saliva.
Previous studies have reported marked variations in
serum CRP levels with diﬀerent thyroid disease entities [11].
But data on CRP levels in saliva of HT and SAT patients
are lacking in literature. The objective of the study was to
estimate and compare salivary CRP levels in Hashimoto’s
thyroiditis and Subacute thyroiditis.2 International Journal of Inﬂammation
2.MaterialsandMethods
2.1. Study Groups. The patients were recruited from K. S.
Hegde Charitable Hospital, Deralakatte, Mangalore, Kar-
nataka, India.
2.1.1. Hashimoto’s Thyroiditis (HT) Group. It included 30
patients with the diagnosis of Hashimoto’s thyroiditis. The
diagnosis was based on increased antithyroglobulin antibody
(Tg-Ab), antithyroid peroxidase antibody (TPO-Ab) titers,
thyroid function tests, and ﬁne-needle aspiration (FNA)
cytology results.
2.1.2. Subacute Granulomatous or de Quervain’s Thyroiditis
(SAT) Group. It consisted of 15 diagnosed patients who were
negativeforTPO-AbandTg-Ab.Theypresentedwithtypical
clinical symptoms such as painful tender goiter and fever.
Their thyroid function test results and FNA cytology results
were compatible with the diagnosis.
2.2. Control Group. It consisted of 20 age- and sex-matched
healthy euthyroid subjects.
Exclusion criteria for the study were the existence of any
comorbid cardiac, autoimmune, infectious, musculoskeletal,
or malignant disease, oral disease, and a recent history of
operation or trauma.
Womenwerepremenopausalandnonewaspregnant.No
individual was following any drug regimen.
2.3. Biochemical Evaluations. TSH and thyroid hormone
levels were measured in all subjects. Serum Total T3
( T T 3 ) ,T o t a lT 4( T T 4 ) ,a n dT S Hl e v e l sw e r em e a s u r e d
by Electrochemiluminescence (Elecsys 2010, Germany). Tg-
Ab and TPO-Ab were measured by Solid phase enzyme
immunoassay (Hycore Biomedicals Ltd, Germany). Erythro-
cyte sedimentation rate (ESR) was measured by Westergren
method. Normal ranges in our laboratory are as fol-
lows: TT3, 0.8–1.8ng/mL; TT4, 4.5–11.5μg/dl; TSH, 0.40–
5.5mIU/liter; Tg-Ab, less than 225IU/mL; TPO-Ab, less
than 35U/mL; ESR, less than 20mm/h (female), 10mm/h
(male).
2.4. Ethics. T h ep r o c e d u r e sf o l l o w e dw e r ei na c c o r d a n c e
with the ethical standards of the Institutional Human Ethics
Committee and with the Helsinki Declaration. The study
was approved by the Institutional Ethics Committee. Before
initiation of the study, voluntary consent was obtained from
each subject.
2.5. Collection of Saliva Samples. Unstimulated whole saliva
wascollectedbypassivedroolingasdescribedpreviously[12]
at least 2 hours after any food intake. Brieﬂy, after 3-4 rinses
of the mouth with water, saliva was allowed to accumulate
in the ﬂoor of the mouth for approximately 2 minutes and
repeatedly expectorated into an ice-chilled polypropylene
vial to collect about 2mL. Following collection, the samples
were stored below −20◦C until their analyses.
Figure 1: Numerous multinucleated histiocytic giant cells and
scant epithelioid cells seen in thyroid tissue of woman presenting
with Subacute thyroiditis (May-Grunwald-Giemsa stain; original
magniﬁcation 450, reduced by 30%).
2.6. Estimation of C-Reactive Protein in Saliva. The concen-
tration of CRP in saliva was estimated by ELISA method
using Salimetrics C-reactive protein ELISA kit (PA, USA).
2.7. Statistical Analysis. Data were analyzed with SPSS-17.00
using one-way analysis of variance (ANOVA) method and
Turkey multiple comparison test. Chi-square test was used
f o rc o m p a r i s o no fg e n d e rd i ﬀerences between the study
groups. P values lower than .05 were considered to be
statistically signiﬁcant.
3. Results
3.1. Characteristics of the Groups. There was no signiﬁcant
diﬀerence in terms of age, gender, between the HT, SAT, and
control groups (Table 1). The TSH titers of the HT patients
were signiﬁcantly higher when compared to SAT and control
subjects. Mean TT3 and TT4 levels were below the normal
lower limit in HT group indicating that the patients were in
hypothyroid state. Mean TT3 and TT4 levels were above the
normal upper limit in SAT group indicating that the patients
were in hyperthyroid state. The ESRs with a mean value of
61.82mm/h were signiﬁcantly higher in the SAT group when
compared to the control and HT groups (Table 1).
3.2. Cytomorphological Features Observed after FNA of Thy-
roid. In SAT group, There exist epithelioid cell granulomas
with multinucleate giant cells, acute and chronic inﬂamma-
torycells,follicularepithelialcellswithdegenerativechanges,
and cellular debris in the background (Figure 1).
In HT group, There exist oxyphilic epithelial cells
(Askanazy cells), moderate to large number of lymphocytes,
fewplasmacellsadmixedwithandsurroundingtheepithelial
cells, variable number of epithelioid histiocytes, scanty or no
colloid, and hemorrhagic background (Figure 2).
3.3. Saliva C-Reactive Protein Levels in HT, SAT, and Controls.
Mean CRP level in saliva of HT (hypothyroid) group was
not signiﬁcantly diﬀerent when compared to the euthyroid
control group (Table 2). However, mean CRP level in saliva
of SAT (hyperthyroid) group was signiﬁcantly higher whenInternational Journal of Inﬂammation 3
Table 1: Characteristics of HT, SAT, and Control Groups.
Hashimoto thyroiditis Subacute thyroiditis Control group
(n = 30) (n = 15) (n = 20)
Age (Yrs) 28.85 ±8.83a 31.75 ±10.40a 31.82 ±9.39a
Gender (F/M) 28/2b 14/1b 17/3b
TSH (mIU/L) 34.25 ±26.28cΨ 0.03 ±0.02d 2.17 ±1.05
TT3 (ng/ml) 0.48 ±0.25cΨ 2.20 ±0.36c 1.09 ±0.25
TT4 (μg/dl ) 2.24 ±1.53cΨ 13.43 ±0.35c 8.38 ±1.65
ESR (mm/h) 22.62 ±8.41dΨ 61.82 ±9.75c 18.77 ±6.44
Data are reported as Mean ± SD
∗P value <. 05 is considered to be statistically signiﬁcant
aP = .456; NS (not signiﬁcant)
bP = .563; NS
cP <. 001; dP >. 05; compared with control values
ΨP <. 001; compared with SAT values.
Figure 2: Numerous oxyphilic epithelial cells (Askanazy cells),
moderate to large number of lymphocytes in a hemorrhagic
background seen in thyroid tissue of woman presenting with
Hashimoto’s thyroiditis (May-Grunwald-Giemsa stain; original
magniﬁcation 450, reduced by 30%).
Table 2: Saliva CRP Levels in HT, SAT, and Control Groups.
Group CRP Levels μg/L
Hashimoto’s thyroiditis (n = 30) 0.817 ±0.206a
Subacute thyroiditis (n = 15) 1.908 ±0.752cb
Control (n = 20) 0.837 ± 0.450
Data are reported as Mean ± SD
P value <. 05 is considered to be statistically signiﬁcant
aP = .987; NS (not signiﬁcant); cP = .001; compared with control values
bP = .001; compared with HT values.
compared to the euthyroid control group (Table 2). Mean
salivaryCRPlevelofSAT(hyperthyroid)groupwasobserved
to be signiﬁcantly higher than the HT (hypothyroid) group
(Table 2).
4. Discussion
The results of our study demonstrated higher salivary CRP
levels in SAT patients who presented with clinical features
of hyperthyroidism when compared to HT patients who
presented with clinical features of hypothyroidism and
euthyroid control subjects. This is not surprising because
the hallmark of the laboratory evaluation of SAT is a
markedlyelevatedESRandelevatedseruminterleukin-6(IL-
6) levels [13], as well as other inﬂammatory markers. CRP
secretion is increased in response to a complex network of
cytokines, especially IL-6 and either IL-1 or tumor necrosis
factor (TNF-α)[ 5]. These results of CRP in saliva are in
concordance with previously reported ﬁndings by Pearce
et al. that serum CRP levels were elevated in patients
with painful subacute thyroiditis [11], which conceivably
reﬂects the presence of an underlying systemic inﬂammatory
process.
There are few data in the literature regarding the
relationship between serum and saliva levels of CRP. CRP
in human saliva measured by application of a microchip
assay system has been shown to positively correlate with
serum CRP estimated by ELISA [8]. Elevated serum and
salivary CRP levels have been reported in patients with
psoriasis [14, 15]. Positive correlation between porcine
serum and salivary CRP has been reported [16]. In all those
studies, salivary CRP concentration was able to distinguish
the healthy from the diseased. The present study did not
involve simultaneous serum CRP estimations. However, the
above-mentioned previous reports [8, 14–16], ﬁndings of
elevated serum CRP levels in SAT patients reported by
Pearce et al. [11], and the demonstration of increased
saliva CRP levels in SAT patients of the present study
indirectly suggest the possibility of the existence of a positive
correlation between saliva and serum CRP levels in the
subjects. However, further studies need to be done to
establish the association between serum and saliva levels of
CRP.
The concentrations of most molecules present in saliva
are usually one tenth to one thousandth of those in blood
[9]. In the present study, the estimated mean concentration
of salivary CRP in normal controls (0.837μg/L; Table 2)
is observed to be approximately 1000-fold lower than the
reported normal levels for serum CRP (0–8mg/L) [17].
The estimated mean concentration of salivary CRP in
the present study in HT (0.817μg/L; Table 2)i so b s e r v e d
to be approximately 3000-fold lower than the reported4 International Journal of Inﬂammation
mean concentration of serum CRP in HT by Pearce et al.
(2.80mg/L) [11]. According to the knowledge of the authors,
there are no other reports in literature on estimation of CRP
in saliva of HT or SAT patients.
Mean CRP level in saliva of HT (hypothyroid) group
of the present study was not signiﬁcantly diﬀerent when
compared to the euthyroid control group. These results are
in concordance with studies by Pearce et al. [11], Sacide et al.
[18], and Kon and DeGroot [19] which reported that serum
CRP levels are not signiﬁcantly increased in patients with
HT. However, the studies by Pearce et al. [11]a n dS a c i d e
et al. [18] involved HT subjects at euthyroid status while
patients of our HT group were in hypothyroid status. But
the study by Kon and DeGroot [19] included patients with
painful HT who presented with hypothyroidism. Therefore,
CRP levels in HT appear to be independent from thyroid
function status.
Regarding the association between thyroid hormone
levels and serum CRP, previous studies have reﬂected
conﬂicting observations. Tuzcu et al. and Christ-Crain et
al. had shown a clear association between hypothyroidism
and raised serum CRP [20, 21]. Taddei et al. reported
higher serum CRP and IL-6 levels in patients with HT
who presented with clinical features of subclinical hypothy-
roidism (SCH) when compared to healthy controls [22].
In contrast, Pearce et al. had shown that patients with HT,
short-term hypothyroidism, and postpartum thyroiditis at
diﬀerent stages (thyrotoxic, euthyroid, or hypothyroid) had
similar serum CRP as compared to their euthyroid controls
[11].ThestudybyHuestonetal.alsoshowednodiﬀerencein
serum CRP levels between patients with SCH and euthyroid
individuals[23].Christ-Crainetal.reportedthatserumCRP
levelsdidnotcorrelatewiththyroidhormonelevelsingroups
of overtly and subclinically hypothyroid subjects and that
treatment of subclinical hypothyroidism did not alter serum
CRP values [21].
With respect to the matter of whether systemic inﬂam-
mation exists in HT, Taddei et al. [22] hypothetically
thought the inﬂammatory process in HT to be related to the
increasedTSHlevelsanddiscussedtheprobabilityofchronic
activation of the immune system due to HT. Mazziotti
et al. demonstrated that patients aﬀe c t e db yH Tw i t h o u t
other apparent autoimmune disorders have a generalized
activation of the immune system [24]. The study by Sacide et
al. revealed low-grade systemic inﬂammation with extremely
high values for another acute phase protein, serum amyloid
A (SAA) in HT patients (euthyroid) when compared to
the controls [18]. Therefore, although salivary CRP level is
theoretically promising as a way to assess inﬂammation, it
appearstohaveonlyalimitedroleinHT.Nevertheless,itmay
prove to be useful in diﬀerentiating between HT and SAT.
The acute phase reaction is in most circumstances a good
indicator of inﬂammatory activity and tissue damage. CRP is
adirectandquantitativemeasurefortheacutephasereaction
and, due to its fast kinetics, provides adequate information
of the actual situation. The ESR, on the contrary, is in fact
an indirect measure of the acute phase reaction. It does
react much slower to changes of inﬂammatory activity and
is inﬂuenced by a number of other factors [5].
The major advantages for using saliva-based assays have
been described in some detail previously [8–10]. Most
importantly, collection of saliva may be done by procedures
that are considered to be noninvasive, painless, and con-
venient. Consequently, these methods may be performed
several times a day. The use of saliva for CRP estimation in
SAT patients could therefore allow the evaluation of their
inﬂammatory status by using non-invasive and minimally
stressful sampling methodology.
In conclusion, CRP levels estimated in saliva of SAT
patients were observed to be signiﬁcantly increased com-
pared to HT patients and euthyroid controls in our study.
The rise in saliva CRP levels in SAT patients conceivably
reﬂects the presence of an underlying systemic inﬂammatory
process. Saliva CRP levels appear to serve as inﬂammatory
markers in SAT patients and, therefore, may aid clinical
evaluation of the patients.
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